Storm Therapeutics has received a biomedical catalyst grant from Innovate UK to research and develop new therapies against the SARS-CoV-2 protein.
The company will use its epigenetic ribonucleic acid (RNA) platform to develop drugs.
The latest grant will help the company develop a drug that can act on an important coronavirus protein that is not targeted to current therapies.
The development of such a drug will offer a valuable option for the treatment of Covid-19 as well as other coronavirus diseases and may be used in conjunction with current therapeutic approaches to treat or treat any urgent treatment-resistant virus strains.
Storm Therapeutics Chairman Tim Edwards said: “We are pleased that Storm’s world-leading experience in this field has been recognized by Innovate UK to help us implement our research and development platform to help in the global fight against Covid-19. .
“Storm’s unique platform paves the way for the discovery of first-class drugs to treat disease by modulating RNA-modifying enzymes.
“The drug we are developing has the potential to be effective against other viruses in the coronavirus family and to be an effective treatment option for patients in any future outbreak of the coronavirus family.”
Storm discovered a treatment with small molecules that act on the epigenetic mechanisms of RNA.
Its new drug discovery platform will facilitate the discovery of first-class inhibitors that can act on RNA-modifying enzymes for oncology, infections and inflammatory diseases.
The platform is illustrated by the company’s METTL3 inhibitor, STC-15, which is scheduled to enter Phase I clinical trials in the second half of this year.
STC-15 will be analyzed for its potential as an oral immunological agent for potential treatment of several human malignancies.